---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287122297.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares rose 6.34% to $9.73, outperforming competitors on a strong trading day. The NASDAQ Composite Index increased by 1.54%, while the Dow Jones Industrial Average rose 1.31%. Despite the gain, CRBP remains 52.68% below its 52-week high of $20.56. Trading volume reached 289,195, surpassing its 50-day average of 261,108."
datetime: "2026-05-20T21:20:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287122297.md)
  - [en](https://longbridge.com/en/news/287122297.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287122297.md)
---

# Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) rose 6.34% to $9.73 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index rising 1.54% to 26,270.36 and the Dow Jones Industrial Average rising 1.31% to 50,009.35.

The stock's rise snapped a four-day losing streak.

Corbus Pharmaceuticals Holdings Inc. closed 52.68% below its 52-week high of $20.56, which the company achieved on October 20th.

The stock outperformed some of its competitors Wednesday, as Vanda Pharmaceuticals Inc. (VNDA) rose 3.17% to $6.18, Fortress Biotech Inc. (FBIO) rose 4.74% to $2.65, and Viking Therapeutics Inc. (VKTX) rose 3.66% to $29.44.

Trading volume (289,195) eclipsed its 50-day average volume of 261,108.

Data source: Dow Jones Market Data, FactSet. Data compiled May 20, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-20-26 1720ET

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)